TPCW
BSX icon

TD Private Client Wealth’s Boston Scientific BSX Stock Holding History

TD Private Client Wealth’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$755K Buy
17,691
+4,075
+30% +$221K 0.01% 417
2026
Q1 		$854K Sell
13,616
-18,062
-57% -$1.44M 0.02% 391
2025
Q4 		$3.02M Sell
31,678
-8,399
-21% -$823K 0.06% 193
2025
Q3 		$3.91M Buy
40,077
+605
+2% +$62.7K 0.09% 159
2025
Q2 		$4.24M Sell
39,472
-1,304
-3% -$132K 0.1% 144
2025
Q1 		$4.11M Buy
40,776
+1,569
+4% +$158K 0.11% 126
2024
Q4 		$3.5M Sell
39,207
-11,791
-23% -$1.04M 0.1% 149
2024
Q3 		$4.27M Sell
50,998
-389
-0.8% -$30.7K 0.12% 126
2024
Q2 		$3.96M Sell
51,387
-956
-2% -$70K 0.12% 124
2024
Q1 		$3.58M Sell
52,343
-27,018
-34% -$1.74M 0.12% 143
2023
Q4 		$4.59M Sell
79,361
-33,745
-30% -$1.8M 0.17% 109
2023
Q3 		$5.97M Sell
113,106
-8,999
-7% -$472K 0.26% 73
2023
Q2 		$6.6M Sell
122,105
-29,085
-19% -$1.52M 0.29% 68
2023
Q1 		$7.56M Sell
151,190
-9,079
-6% -$428K 0.34% 54
2022
Q4 		$7.42M Sell
160,269
-1,959
-1% -$84.8K 0.35% 55
2022
Q3 		$6.28M Buy
162,228
+14,673
+10% +$589K 0.32% 61
2022
Q2 		$5.5M Buy
147,555
+29,930
+25% +$1.22M 0.27% 81
2022
Q1 		$5.21M Buy
117,625
+10,417
+10% +$451K 0.22% 105
2021
Q4 		$4.55M Buy
107,208
+6,136
+6% +$258K 0.19% 123
2021
Q3 		$4.39M Buy
101,072
+20,383
+25% +$902K 0.19% 117
2021
Q2 		$3.45M Buy
80,689
+23,658
+41% +$995K 0.15% 157
2021
Q1 		$2.2M Buy
57,031
+2,449
+4% +$92.7K 0.1% 213
2020
Q4 		$1.96M Sell
54,582
-52,495
-49% -$1.89M 0.1% 217
2020
Q3 		$4.09M Sell
107,077
-10,610
-9% -$409K 0.23% 98
2020
Q2 		$4.13M Buy
117,687
+10,748
+10% +$387K 0.24% 87
2020
Q1 		$3.49M Buy
106,939
+11,682
+12% +$456K 0.25% 92
2019
Q4 		$4.31M Buy
+95,257
New +$3.99M 0.26% 91

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TD Private Client Wealth's BSX Position: Q2 2026 in Review

TD Private Client Wealth increased its Boston Scientific (BSX) stake by 30% in Q2 2026, buying an estimated $221K and bringing the position to 17,691 shares worth $755K. The position accounts for 0.01% of the portfolio, ranked #417.

TD Private Client Wealth first reported a position in BSX in Q4 2019 and has held it in 27 quarters since. The position peaked at $7.56M in Q1 2023. 1,476 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • TD Private Client Wealth held 17,691 shares of Boston Scientific worth $755K as of Q2 2026.
  • TD Private Client Wealth bought 4,075 Boston Scientific shares in Q2 2026, an estimated $221K.
  • Boston Scientific made up 0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #417 holding.
  • TD Private Client Wealth first reported a position in Boston Scientific in Q4 2019 and has held it in 27 quarters since.
  • TD Private Client Wealth's Boston Scientific position peaked at $7.56M in Q1 2023.
  • 1,476 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.